Merck: Ever More Willing to Share
Executive Summary
The famously insular Merck & Co. has embarked on a late-stage feeding frenzy, ceding an unprecedented amount of marketing control to its new partners in return for marketing rights. Three of Merck's next four drug introductions will likely be co-promotions: ezetimibe/simvastatin (Vytorin), with Schering-Plough, gaboxadol, from H. Lundbeck, and now muraglitazar, from Bristol-Myers Squibb.